 |
PDBsum entry 1fj4
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
The structure of beta-ketoacyl-[acyl carrier protein] synthase i in complex with thiolactomycin, implications for drug design
|
|
Structure:
|
 |
Beta-ketoacyl-[acyl carrier protein] synthase i. Chain: a, b, c, d. Engineered: yes
|
|
Source:
|
 |
Escherichia coli. Organism_taxid: 562. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.35Å
|
R-factor:
|
0.197
|
R-free:
|
0.253
|
|
|
Authors:
|
 |
A.C.Price,K.Choi,R.J.Heath,Z.Li,S.W.White,C.O.Rock
|
Key ref:
|
 |
A.C.Price
et al.
(2001).
Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism.
J Biol Chem,
276,
6551-6559.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
07-Aug-00
|
Release date:
|
23-Aug-00
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P0A953
(FABB_ECOLI) -
3-oxoacyl-[acyl-carrier-protein] synthase 1 from Escherichia coli (strain K12)
|
|
|
|
Seq: Struc:
|
 |
 |
 |
406 a.a.
403 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.3.1.41
- beta-ketoacyl-[acyl-carrier-protein] synthase I.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a fatty acyl-[ACP] + malonyl-[ACP] + H+ = a 3-oxoacyl-[ACP] + holo- [ACP] + CO2
|
 |
 |
 |
 |
 |
fatty acyl-[ACP]
|
+
|
malonyl-[ACP]
|
+
|
H(+)
|
=
|
3-oxoacyl-[ACP]
|
+
|
holo- [ACP]
|
+
|
CO2
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
276:6551-6559
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism.
|
|
A.C.Price,
K.H.Choi,
R.J.Heath,
Z.Li,
S.W.White,
C.O.Rock.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The beta-ketoacyl-acyl carrier protein (ACP) synthases are key regulators of
type II fatty acid synthesis and are the targets for two natural products,
thiolactomycin (TLM) and cerulenin. The high resolution structures of the
FabB-TLM and FabB-cerulenin binary complexes were determined. TLM mimics
malonyl-ACP in the FabB active site. It forms strong hydrogen bond interactions
with the two catalytic histidines, and the unsaturated alkyl side chain
interaction with a small hydrophobic pocket is stabilized by pi stacking
interactions. Cerulenin binding mimics the condensation transition state. The
subtle differences between the FabB-cerulenin and FabF-cerulenin (Moche, M.,
Schneider, G., Edwards, P., Dehesh, K., and Lindqvist, Y. (1999) J. Biol. Chem.
244, 6031-6034) structures explain the differences in the sensitivity of the two
enzymes to the antibiotic and may reflect the distinct substrate specificities
protein was prepared to
convert the FabB His-His-Cys active site triad into the FabH His-Asn-Cys
configuration to test the importance of the two His residues in TLM and
was significantly more resistant to both
antibiotics than FabB and had an affinity for TLM an order of magnitude less
than the wild-type enzyme, illustrating that the two-histidine active site
architecture is critical to protein-antibiotic interaction. These data provide a
structural framework for understanding antibiotic sensitivity within this group
of enzymes.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 7.
Fig. 7. Overlay of TLM and cerulenin in the FabB active
site. The FabB-TLM and FabB-cerulenin structures were
superimposed to illustrate the differences in the binding of the
antibiotics in the active site. The coloring scheme in this
figure is the same as in Figs. 3 and 4. TLM binds on the
malonyl-ACP side and cerulenin occupies the acyl-enzyme
intermediate half. The O-1 of TLM and O-2 of cerulenin are the
only portions of the antibiotics that overlap in the structure,
and they form hydrogen bonds with the His-His dyad in the active
site. Note that the protein structure shown is that of the
FabB-TLM complex. Binding of the two antibiotics results in
essentially identical changes in the conformations of the active
site residues.
|
 |
Figure 8.
Fig. 8. Schematic diagrams illustrating how cerulenin and
TLM mimic substrates in the active site of FabB. Upper panel,
the thiolactone ring of TLM mimics the bent conformation of the
thiomalonate, and this is emphasized by the shaded atoms. The
O-1s form hydrogen bonds with His-298 and His-333, and the C-1,
C-2, and C-3s of malonate are mimicked by the C-1, C-2, and C-9s
of TLM. The O-2 of TLM points out the active site tunnel that
would be occupied by the pantetheine arm of the malonyl-ACP
substrate. Lower panel, cerulenin mimics the condensation
transition state and spans the two halves of the active site.
The O-3 of cerulenin lies in the oxyanion hole formed by the
amides of Cys-163 and Phe-392 enclosed by the phenyl side chain
of Phe-392. This structure mimics the postulated location of the
oxyanion of the tetrahedral transition state. The side chain of
Cys-163 rotates in the cerulenin structure to form a covalent
bond with C-2, but in the transition state, it is postulated to
reside in the location observed in the native enzyme. The acyl
chain of cerulenin feeds into the hydrophobic groove that
accommodates the long chain acyl-enzyme intermediate.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2001,
276,
6551-6559)
copyright 2001.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.A.Machutta,
G.R.Bommineni,
S.R.Luckner,
K.Kapilashrami,
B.Ruzsicska,
C.Simmerling,
C.Kisker,
and
P.J.Tonge
(2010).
Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin.
|
| |
J Biol Chem,
285,
6161-6169.
|
 |
|
|
|
|
 |
D.I.Chan,
and
H.J.Vogel
(2010).
Current understanding of fatty acid biosynthesis and the acyl carrier protein.
|
| |
Biochem J,
430,
1.
|
 |
|
|
|
|
 |
H.H.Xu,
J.D.Trawick,
R.J.Haselbeck,
R.A.Forsyth,
R.T.Yamamoto,
R.Archer,
J.Patterson,
M.Allen,
J.M.Froelich,
I.Taylor,
D.Nakaji,
R.Maile,
G.C.Kedar,
M.Pilcher,
V.Brown-Driver,
M.McCarthy,
A.Files,
D.Robbins,
P.King,
S.Sillaots,
C.Malone,
C.S.Zamudio,
T.Roemer,
L.Wang,
P.J.Youngman,
and
D.Wall
(2010).
Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials.
|
| |
Antimicrob Agents Chemother,
54,
3659-3670.
|
 |
|
|
|
|
 |
K.Palanichamy,
and
K.P.Kaliappan
(2010).
Discovery and syntheses of "superbug challengers"-platensimycin and platencin.
|
| |
Chem Asian J,
5,
668-703.
|
 |
|
|
|
|
 |
M.Hughes,
V.Snetkov,
R.S.Rose,
S.Trousil,
J.E.Mermoud,
and
C.Dingwall
(2010).
Neurite-like structures induced by mevalonate pathway blockade are due to the stability of cell adhesion foci and are enhanced by the presence of APP.
|
| |
J Neurochem,
114,
832-842.
|
 |
|
|
|
|
 |
R.Orth,
T.Böttcher,
and
S.A.Sieber
(2010).
The biological targets of acivicin inspired 3-chloro- and 3-bromodihydroisoxazole scaffolds.
|
| |
Chem Commun (Camb),
46,
8475-8477.
|
 |
|
|
|
|
 |
J.M.Draper,
and
C.D.Smith
(2009).
Palmitoyl acyltransferase assays and inhibitors (Review).
|
| |
Mol Membr Biol,
26,
5.
|
 |
|
|
|
|
 |
K.C.Nicolaou,
J.S.Chen,
D.J.Edmonds,
and
A.A.Estrada
(2009).
Recent advances in the chemistry and biology of naturally occurring antibiotics.
|
| |
Angew Chem Int Ed Engl,
48,
660-719.
|
 |
|
|
|
|
 |
K.Ohata,
and
S.Terashima
(2009).
Synthesis and biological activity of enantiomeric pairs of 5-(Alk-2-enyl)thiolactomycin and 5-[(E)-Cycloalk-2-enylidenemethyl]thiolactomycin congeners.
|
| |
Chem Pharm Bull (Tokyo),
57,
920-936.
|
 |
|
|
|
|
 |
P.J.Lee,
J.B.Bhonsle,
H.W.Gaona,
D.P.Huddler,
T.N.Heady,
M.Kreishman-Deitrick,
A.Bhattacharjee,
W.F.McCalmont,
L.Gerena,
M.Lopez-Sanchez,
N.E.Roncal,
T.H.Hudson,
J.D.Johnson,
S.T.Prigge,
and
N.C.Waters
(2009).
Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents.
|
| |
J Med Chem,
52,
952-963.
|
 |
|
|
|
|
 |
P.J.McNamara,
R.E.Syverson,
K.Milligan-Myhre,
O.Frolova,
S.Schroeder,
J.Kidder,
T.Hoang,
and
R.A.Proctor
(2009).
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
|
| |
Antimicrob Agents Chemother,
53,
1898-1906.
|
 |
|
|
|
|
 |
Q.Al-Balas,
N.G.Anthony,
B.Al-Jaidi,
A.Alnimr,
G.Abbott,
A.K.Brown,
R.C.Taylor,
G.S.Besra,
T.D.McHugh,
S.H.Gillespie,
B.F.Johnston,
S.P.Mackay,
and
G.D.Coxon
(2009).
Identification of 2-Aminothiazole-4-Carboxylate Derivatives Active against Mycobacterium tuberculosis H(37)R(v) and the beta-Ketoacyl-ACP Synthase mtFabH.
|
| |
PLoS ONE,
4,
e5617.
|
 |
|
|
|
|
 |
S.Brinster,
G.Lamberet,
B.Staels,
P.Trieu-Cuot,
A.Gruss,
and
C.Poyart
(2009).
Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens.
|
| |
Nature,
458,
83-86.
|
 |
|
|
|
|
 |
S.R.Luckner,
C.A.Machutta,
P.J.Tonge,
and
C.Kisker
(2009).
Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.
|
| |
Structure,
17,
1004-1013.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.Bagautdinov,
Y.Ukita,
M.Miyano,
and
N.Kunishima
(2008).
Structure of 3-oxoacyl-(acyl-carrier protein) synthase II from Thermus thermophilus HB8.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun,
64,
358-366.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.Parthasarathy,
R.Cummings,
J.W.Becker,
and
S.M.Soisson
(2008).
Surface-entropy reduction approaches to manipulate crystal forms of beta-ketoacyl acyl carrier protein synthase II from Streptococcus pneumoniae.
|
| |
Acta Crystallogr D Biol Crystallogr,
64,
141-148.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.Johansson,
B.Wiltschi,
P.Kumari,
B.Kessler,
C.Vonrhein,
J.Vonck,
D.Oesterhelt,
and
M.Grininger
(2008).
Inhibition of the fungal fatty acid synthase type I multienzyme complex.
|
| |
Proc Natl Acad Sci U S A,
105,
12803-12808.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.N.Brown,
and
P.A.Gulig
(2008).
Regulation of fatty acid metabolism by FadR is essential for Vibrio vulnificus to cause infection of mice.
|
| |
J Bacteriol,
190,
7633-7644.
|
 |
|
|
|
|
 |
A.Bhatt,
V.Molle,
G.S.Besra,
W.R.Jacobs,
and
L.Kremer
(2007).
The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development.
|
| |
Mol Microbiol,
64,
1442-1454.
|
 |
|
|
|
|
 |
C.E.Christensen,
B.B.Kragelund,
P.von Wettstein-Knowles,
and
A.Henriksen
(2007).
Structure of the human beta-ketoacyl [ACP] synthase from the mitochondrial type II fatty acid synthase.
|
| |
Protein Sci,
16,
261-272.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.J.Ferguson,
S.A.Campbell,
F.L.Henriquez,
L.Phan,
E.Mui,
T.A.Richards,
S.P.Muench,
M.Allary,
J.Z.Lu,
S.T.Prigge,
F.Tomley,
M.W.Shirley,
D.W.Rice,
R.McLeod,
and
C.W.Roberts
(2007).
Enzymes of type II fatty acid synthesis and apicoplast differentiation and division in Eimeria tenella.
|
| |
Int J Parasitol,
37,
33-51.
|
 |
|
|
|
|
 |
F.Kudo,
Y.Kasama,
T.Hirayama,
and
T.Eguchi
(2007).
Cloning of the pactamycin biosynthetic gene cluster and characterization of a crucial glycosyltransferase prior to a unique cyclopentane ring formation.
|
| |
J Antibiot (Tokyo),
60,
492-503.
|
 |
|
|
|
|
 |
G.Pappenberger,
T.Schulz-Gasch,
E.Kusznir,
F.Müller,
and
M.Hennig
(2007).
Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis.
|
| |
Acta Crystallogr D Biol Crystallogr,
63,
1208-1216.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.T.Wright,
and
K.A.Reynolds
(2007).
Antibacterial targets in fatty acid biosynthesis.
|
| |
Curr Opin Microbiol,
10,
447-453.
|
 |
|
|
|
|
 |
J.Wang,
S.Kodali,
S.H.Lee,
A.Galgoci,
R.Painter,
K.Dorso,
F.Racine,
M.Motyl,
L.Hernandez,
E.Tinney,
S.L.Colletti,
K.Herath,
R.Cummings,
O.Salazar,
I.González,
A.Basilio,
F.Vicente,
O.Genilloud,
F.Pelaez,
H.Jayasuriya,
K.Young,
D.F.Cully,
and
S.B.Singh
(2007).
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
|
| |
Proc Natl Acad Sci U S A,
104,
7612-7616.
|
 |
|
|
|
|
 |
J.Z.Lu,
S.P.Muench,
M.Allary,
S.Campbell,
C.W.Roberts,
E.Mui,
R.L.McLeod,
D.W.Rice,
and
S.T.Prigge
(2007).
Type I and type II fatty acid biosynthesis in Eimeria tenella: enoyl reductase activity and structure.
|
| |
Parasitology,
134,
1949-1962.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.L.Dormann,
and
R.Brückner
(2007).
Variable synthesis of the optically active thiotetronic acid antibiotics thiolactomycin, thiotetromycin, and 834-B1.
|
| |
Angew Chem Int Ed Engl,
46,
1160-1163.
|
 |
|
|
|
|
 |
M.M.Alhamadsheh,
F.Musayev,
A.A.Komissarov,
S.Sachdeva,
H.T.Wright,
N.Scarsdale,
G.Florova,
and
K.A.Reynolds
(2007).
Alkyl-CoA disulfides as inhibitors and mechanistic probes for FabH enzymes.
|
| |
Chem Biol,
14,
513-524.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.J.Kridel,
W.T.Lowther,
and
C.W.Pemble
(2007).
Fatty acid synthase inhibitors: new directions for oncology.
|
| |
Expert Opin Investig Drugs,
16,
1817-1829.
|
 |
|
|
|
|
 |
S.Sharma,
S.K.Sharma,
R.Modak,
K.Karmodiya,
N.Surolia,
and
A.Surolia
(2007).
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
|
| |
Antimicrob Agents Chemother,
51,
2552-2558.
|
 |
|
|
|
|
 |
S.Sridharan,
L.Wang,
A.K.Brown,
L.G.Dover,
L.Kremer,
G.S.Besra,
and
J.C.Sacchettini
(2007).
X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB).
|
| |
J Mol Biol,
366,
469-480.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Tang,
A.Y.Chen,
C.Y.Kim,
D.E.Cane,
and
C.Khosla
(2007).
Structural and mechanistic analysis of protein interactions in module 3 of the 6-deoxyerythronolide B synthase.
|
| |
Chem Biol,
14,
931-943.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.M.Haapalainen,
G.Meriläinen,
and
R.K.Wierenga
(2006).
The thiolase superfamily: condensing enzymes with diverse reaction specificities.
|
| |
Trends Biochem Sci,
31,
64-71.
|
 |
|
|
|
|
 |
C.Oefner,
H.Schulz,
A.D'Arcy,
and
G.E.Dale
(2006).
Mapping the active site of Escherichia coli malonyl-CoA-acyl carrier protein transacylase (FabD) by protein crystallography.
|
| |
Acta Crystallogr D Biol Crystallogr,
62,
613-618.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.Häbich,
and
F.von Nussbaum
(2006).
Platensimycin, a new antibiotic and "superbug challenger" from nature.
|
| |
ChemMedChem,
1,
951-954.
|
 |
|
|
|
|
 |
J.Wang,
S.M.Soisson,
K.Young,
W.Shoop,
S.Kodali,
A.Galgoci,
R.Painter,
G.Parthasarathy,
Y.S.Tang,
R.Cummings,
S.Ha,
K.Dorso,
M.Motyl,
H.Jayasuriya,
J.Ondeyka,
K.Herath,
C.Zhang,
L.Hernandez,
J.Allocco,
A.Basilio,
J.R.Tormo,
O.Genilloud,
F.Vicente,
F.Pelaez,
L.Colwell,
S.H.Lee,
B.Michael,
T.Felcetto,
C.Gill,
L.L.Silver,
J.D.Hermes,
K.Bartizal,
J.Barrett,
D.Schmatz,
J.W.Becker,
D.Cully,
and
S.B.Singh
(2006).
Platensimycin is a selective FabF inhibitor with potent antibiotic properties.
|
| |
Nature,
441,
358-361.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Young,
H.Jayasuriya,
J.G.Ondeyka,
K.Herath,
C.Zhang,
S.Kodali,
A.Galgoci,
R.Painter,
V.Brown-Driver,
R.Yamamoto,
L.L.Silver,
Y.Zheng,
J.I.Ventura,
J.Sigmund,
S.Ha,
A.Basilio,
F.Vicente,
J.R.Tormo,
F.Pelaez,
P.Youngman,
D.Cully,
J.F.Barrett,
D.Schmatz,
S.B.Singh,
and
J.Wang
(2006).
Discovery of FabH/FabF inhibitors from natural products.
|
| |
Antimicrob Agents Chemother,
50,
519-526.
|
 |
|
|
|
|
 |
P.Kim,
C.E.Barry,
and
C.S.Dowd
(2006).
Novel route to 5-position vinyl derivatives of thiolactomycin: Olefination vs. deformylation.
|
| |
Tetrahedron Lett,
47,
3447-3451.
|
 |
|
|
|
|
 |
P.Kim,
Y.M.Zhang,
G.Shenoy,
Q.A.Nguyen,
H.I.Boshoff,
U.H.Manjunatha,
M.B.Goodwin,
J.Lonsdale,
A.C.Price,
D.J.Miller,
K.Duncan,
S.W.White,
C.O.Rock,
C.E.Barry,
and
C.S.Dowd
(2006).
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
|
| |
J Med Chem,
49,
159-171.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.von Wettstein-Knowles,
J.G.Olsen,
K.A.McGuire,
and
A.Henriksen
(2006).
Fatty acid synthesis. Role of active site histidines and lysine in Cys-His-His-type beta-ketoacyl-acyl carrier protein synthases.
|
| |
FEBS J,
273,
695-710.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Punjabi,
and
P.Traktman
(2005).
Cell biological and functional characterization of the vaccinia virus F10 kinase: implications for the mechanism of virion morphogenesis.
|
| |
J Virol,
79,
2171-2190.
|
 |
|
|
|
|
 |
N.Sirinupong,
P.Suwanmanee,
R.F.Doolittle,
and
W.Suvachitanont
(2005).
Molecular cloning of a new cDNA and expression of 3-hydroxy-3-methylglutaryl-CoA synthase gene from Hevea brasiliensis.
|
| |
Planta,
221,
502-512.
|
 |
|
|
|
|
 |
R.J.Wilson
(2005).
Parasite plastids: approaching the endgame.
|
| |
Biol Rev Camb Philos Soc,
80,
129-153.
|
 |
|
|
|
|
 |
S.W.White,
J.Zheng,
Y.M.Zhang,
and
Rock
(2005).
The structural biology of type II fatty acid biosynthesis.
|
| |
Annu Rev Biochem,
74,
791-831.
|
 |
|
|
|
|
 |
X.Qiu,
A.E.Choudhry,
C.A.Janson,
M.Grooms,
R.A.Daines,
J.T.Lonsdale,
and
S.S.Khandekar
(2005).
Crystal structure and substrate specificity of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus.
|
| |
Protein Sci,
14,
2087-2094.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Z.J.Witczak,
and
J.M.Culhane
(2005).
Thiosugars: new perspectives regarding availability and potential biochemical and medicinal applications.
|
| |
Appl Microbiol Biotechnol,
69,
237-244.
|
 |
|
|
|
|
 |
G.Shenoy,
P.Kim,
M.Goodwin,
Q.A.Nguyen,
C.E.Barry,
and
C.S.Dowd
(2004).
SYNTHESIS AND SPECTROSCOPIC DIFFERENTIATION OF 2- AND 4-ALKOXYTHIOTETRONIC ACIDS.
|
| |
Heterocycles,
63,
519-527.
|
 |
|
|
|
|
 |
R.J.Heath,
and
C.O.Rock
(2004).
Fatty acid biosynthesis as a target for novel antibacterials.
|
| |
Curr Opin Investig Drugs,
5,
146-153.
|
 |
|
|
|
|
 |
X.He,
A.M.Reeve,
U.R.Desai,
G.E.Kellogg,
and
K.A.Reynolds
(2004).
1,2-dithiole-3-ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein synthase III (FabH).
|
| |
Antimicrob Agents Chemother,
48,
3093-3102.
|
 |
|
|
|
|
 |
Y.J.Lu,
Y.M.Zhang,
and
C.O.Rock
(2004).
Product diversity and regulation of type II fatty acid synthases.
|
| |
Biochem Cell Biol,
82,
145-155.
|
 |
|
|
|
|
 |
A.C.Price,
C.O.Rock,
and
S.W.White
(2003).
The 1.3-Angstrom-resolution crystal structure of beta-ketoacyl-acyl carrier protein synthase II from Streptococcus pneumoniae.
|
| |
J Bacteriol,
185,
4136-4143.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Ritzenthaler,
C.Laporte,
F.Gaire,
P.Dunoyer,
C.Schmitt,
S.Duval,
A.Piéquet,
A.M.Loudes,
O.Rohfritsch,
C.Stussi-Garaud,
and
P.Pfeiffer
(2002).
Grapevine fanleaf virus replication occurs on endoplasmic reticulum-derived membranes.
|
| |
J Virol,
76,
8808-8819.
|
 |
|
|
|
|
 |
H.Pan,
S.Tsai,
E.S.Meadows,
L.J.Miercke,
A.T.Keatinge-Clay,
J.O'Connell,
C.Khosla,
and
R.M.Stroud
(2002).
Crystal structure of the priming beta-ketosynthase from the R1128 polyketide biosynthetic pathway.
|
| |
Structure,
10,
1559-1568.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Jackowski,
Y.M.Zhang,
A.C.Price,
S.W.White,
and
C.O.Rock
(2002).
A missense mutation in the fabB (beta-ketoacyl-acyl carrier protein synthase I) gene confers tiolactomycin resistance to Escherichia coli.
|
| |
Antimicrob Agents Chemother,
46,
1246-1252.
|
 |
|
|
|
|
 |
T.K.Zank,
U.Zähringer,
C.Beckmann,
G.Pohnert,
W.Boland,
H.Holtorf,
R.Reski,
J.Lerchl,
and
E.Heinz
(2002).
Cloning and functional characterisation of an enzyme involved in the elongation of Delta6-polyunsaturated fatty acids from the moss Physcomitrella patens.
|
| |
Plant J,
31,
255-268.
|
 |
|
|
|
|
 |
X.He,
and
K.A.Reynolds
(2002).
Purification, characterization, and identification of novel inhibitors of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus.
|
| |
Antimicrob Agents Chemother,
46,
1310-1318.
|
 |
|
|
|
|
 |
H.J.Lee,
M.H.Choi,
T.U.Kim,
and
S.C.Yoon
(2001).
Accumulation of polyhydroxyalkanoic acid containing large amounts of unsaturated monomers in Pseudomonas fluorescens BM07 utilizing saccharides and its inhibition by 2-bromooctanoic acid.
|
| |
Appl Environ Microbiol,
67,
4963-4974.
|
 |
|
|
|
|
 |
J.W.Campbell,
and
J.E.Cronan
(2001).
Escherichia coli FadR positively regulates transcription of the fabB fatty acid biosynthetic gene.
|
| |
J Bacteriol,
183,
5982-5990.
|
 |
|
|
|
|
 |
J.W.Campbell,
and
J.E.Cronan
(2001).
Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery.
|
| |
Annu Rev Microbiol,
55,
305-332.
|
 |
|
|
|
|
 |
R.J.Heath
(2001).
Bacterial fatty-acid biosynthesis: an antibacterial drug target waiting to be exploited.
|
| |
Drug Discov Today,
6,
715.
|
 |
|
|
|
|
 |
R.J.Heath,
S.W.White,
and
C.O.Rock
(2001).
Lipid biosynthesis as a target for antibacterial agents.
|
| |
Prog Lipid Res,
40,
467-497.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |